EGFR mutations and EGFR tyrosine kinase inhibitors
A partir de données portant sur 600 patients atteints d'un cancer avancé du poumon non à petites cellules présentant un gène EGFR muté et inclus dans 3 essais de phase III, cette étude évalue l'efficacité de l'afatinib en fonction du type de mutation du gène EGFR
In 2004, three groups independently noted that the presence of activating mutations in patients with advanced non-small-cell lung cancer made tumours sensitive to EGFR tyrosine kinase inhibitors. Since then, nine randomised trials including almost 1800 patients have been done, which have compared chemotherapy with tyrosine kinase inhibitors for first-line treatment of a subpopulation of patients with advanced non-small-cell lung cancer tumours that contained these mutations.